Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F]AlF-P16-093

0
247
P16-093 was labeled with 18F via [18F]AlF2+ complex formation, and the biological properties of [18F]AlF-P16-093 were evaluated. In vitro, [18F]AlF-P16-093 showed prostate-specific membrane antigen (PSMA)-specific high uptakes in PIP-PC3 cells.
[Bioconjugate Chemistry]
Zha, Z., Choi, S. R., Ploessl, K., Alexoff, D., Zhao, R., Zhu, L., & Kung, H. F. (2021). Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F]AlF-P16-093. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.1c00177 Cite
AbstractGraphical Abstract